Jansà J M, Serrano J, Caylà J A, Vidal R, Ocaña I, Español T
Department of Epidemiology, Municipal Institute of Health, Barcelona, Spain.
Int J Tuberc Lung Dis. 1998 Feb;2(2):140-6.
A residential program in Barcelona for drug addicts (therapeutic community) admitted between November 1988 and March 1992, and followed until September 1994.
To study the incidence of tuberculosis as related to the presence of tuberculosis infection and/or human immunodeficiency virus (HIV) infection, and to evaluate the protective effect of chemoprophylaxis with isoniazid.
Prospective cohort study. Incidence rates were compared using the Chi-square test for cohort studies. The effectiveness of chemoprophylaxis was evaluated by the Kaplan-Meier method at the univariate level, and by logistic regression models and proportional risks analysis at the multivariate level.
During the study of 361 individuals without previous known tuberculosis or history of anti-tuberculosis chemoprophylaxis, 25 developed tuberculosis, an overall incidence rate of 1.79/100 person-years. For HIV-positive persons, the incidence rate was 3.25/100 person-years, compared with 0.30/100 in those who were HIV-negative (P < 0.05). The highest incidence rates occurred among HIV-positive persons who did not receive chemoprophylaxis and who were either anergic (HIV-positive, purified protein derivative [PPD]-negative, Multitest-negative) or who were infected with Mycobacterium tuberculosis (PPD+), 10.0/100 person-years and 4.64/100 person-years, respectively. Of the 53 persons who received chemoprophylaxis, three developed tuberculosis, an incidence rate of 1.4/100 person-years. In comparison, in the group of 51 patients who were designated to receive chemoprophylaxis but where none was actually taken, 17 developed tuberculosis, an incidence rate of 5.7/100 person-years (P = 0.03).
HIV-infected intravenous drug users, particularly those who are anergic or who are PPD positive, are at increased risk of developing tuberculosis. Anti-tuberculosis chemoprophylaxis proved effective in this population.
巴塞罗那一个针对吸毒成瘾者的住院项目(治疗社区),研究对象为1988年11月至1992年3月期间收治的患者,并随访至1994年9月。
研究结核病发病率与结核感染和/或人类免疫缺陷病毒(HIV)感染的关系,并评估异烟肼化学预防的保护作用。
前瞻性队列研究。使用队列研究的卡方检验比较发病率。化学预防的有效性在单变量水平上通过Kaplan-Meier方法评估,在多变量水平上通过逻辑回归模型和比例风险分析评估。
在对361名既往无已知结核病或抗结核化学预防史的个体进行的研究中,25人患结核病,总发病率为1.79/100人年。HIV阳性者的发病率为3.25/100人年,而HIV阴性者为0.30/100人年(P<0.05)。发病率最高的是未接受化学预防的HIV阳性者,其中无反应者(HIV阳性,纯蛋白衍生物[PPD]阴性,多重检测阴性)或感染结核分枝杆菌者(PPD阳性),发病率分别为10.0/100人年和4.64/100人年。在接受化学预防的53人中,3人患结核病,发病率为1.4/100人年。相比之下,在指定接受化学预防但实际未接受的51名患者组中,17人患结核病,发病率为5.7/100人年(P = 0.03)。
HIV感染的静脉吸毒者,尤其是无反应者或PPD阳性者,患结核病的风险增加。抗结核化学预防在该人群中被证明是有效的。